Evidence map›Paper›PMID 28410618›Full record

ReviewMolecular cancer2017

Liquid biopsy: a step forward towards precision medicine in urologic malignancies.

Ashley Di Meo, Jenni Bartlett, Yufeng Cheng, Maria D Pasic, George M Yousef

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 185 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
185citing papers in PubMed, 8 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

185 citing papers in PubMed, 8 syntheses or guidelines pooled it, 327 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Urinary microRNAs expression in prostate cancer diagnosis: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Roles of long non-coding RNAs in oesophageal cancer pathogenesis.International journal of experimental pathology · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Article

125 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Ashley Di MeoDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Jenni BartlettDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Yufeng ChengDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Maria D PasicDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
George M YousefDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. yousefg@smh.ca.
University of Toronto · CAQilu Hospital of Shandong University · CNSt Joseph's Health Centre · CASt. Michael's Hospital · CA

Funding

CIHR MOP 119606
6 · The paper itself

Abstract

There is a growing trend towards exploring the use of a minimally invasive "liquid biopsy" to identify biomarkers in a number of cancers, including urologic malignancies. Multiple aspects can be assessed in circulating cell-free DNA, including cell-free DNA levels, integrity, methylation and mutations. Other prospective liquid biopsy markers include circulating tumor cells, circulating RNAs (miRNA, lncRNAs and mRNAs), cell-free proteins, peptides and exosomes have also emerged as non-invasive cancer biomarkers. These circulating molecules can be detected in various biological fluids, including blood, urine, saliva and seminal plasma. Liquid biopsies hold great promise for personalized medicine due to their ability to provide multiple non-invasive global snapshots of the primary and metastatic tumors. Molecular profiling of circulating molecules has been a stepping-stone to the successful introduction of several non-invasive multi-marker tests into the clinic. In this review, we provide an overview of the current state of cell-free DNA-based kidney, prostate and bladder cancer biomarker research and discuss the potential utility other circulating molecules. We will also discuss the challenges and limitations facing non-invasive cancer biomarker discovery and the benefits of this growing area of translational research.

Indexed as

Biomarkers, TumorBiopsyBlood ProteinsDNA, NeoplasmExosomesHumansMutationNeoplastic Cells, CirculatingPeptidesPrecision MedicineRNAUrologic NeoplasmsBiomarkers, TumorBlood ProteinsDNA, NeoplasmPeptidesRNABiomarkersBladder cancerCancer treatmentCell-free DNACirculating tumor cellsCirculating tumor DNAExosomseKidney cancerLiquid biopsyLong non-coding RNAmiRNAsPersonalized medicinePrecision medicinePredictive markersProstate cancerTumor markers

Identifiers

PMID28410618
PMCPMC5391592
OpenAlexW2606403603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.